Bosentan–sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology

D′Alto, Michele; Romeo, Emanuele; Argiento, Paola; Sarubbi, Berardo; Santoro, Giuseppe; Grimaldi, N; Correra, Anna; Scognamiglio, Giancarlo; Russo, Maria Giovanna; Calabrò, Raffaele

doi:10.1016/j.ijcard.2010.10.051

Cited by 110 publications

(56 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, these were stable ES patients and, therefore, the study does not adequately reflect routine clinical practice of initiating combination therapy in patients deteriorating on oral monotherapy. Two observational studies [60,66] in contrast have demonstrated that initiation of dual or combination therapy in ES patients with a clinical indication improves 6MWD and hemodynamics. Therefore, in accordance to current guidelines, combination therapy may be considered in WHO class III ES patients.…”

Section: Eras and Pdesmentioning

confidence: 99%

The challenge of managing pulmonary arterial hypertension in adults with congenital heart disease

Radke

Diller

Baumgartner

2013

Expert Review of Cardiovascular Therapy

View full text Add to dashboard Cite

Section: Eras and Pdesmentioning

confidence: 99%

The challenge of managing pulmonary arterial hypertension in adults with congenital heart disease

Radke

Diller

Baumgartner

2013

Expert Review of Cardiovascular Therapy

View full text Add to dashboard Cite

“…6,7) Pulmonary vasodilator therapy improves outcomes in patients with idiopathic PAH, and has also been reported to be effective in patients with other types of PAH. [8][9][10][11][12][13] This therapy may reduce pulmonary vascular resistance (Rp) in patients who were previously thought to have irreversible pulmonary vascular disease.…”

Section: R Ecent Advances In Pediatric Cardiac Surgery Techniquesmentioning

confidence: 99%

“…6,42) These vasodilators have been shown to improve functional status and survival in patients with idiopathic PAH. [6][7][8][9][10][11][12][13] Pulmonary vasodilator therapy is now being used to treat PAH in patients with CHD, including those with Eisenmenger syndrome. Many reports have indicated that the endothelin receptor antagonist bosentan is effective for improving clinical outcomes and exercise capacity in patients with Eisenmenger syndrome.…”

Section: How Does Pulmonary Vasodilator Therapy Affect Outcomes In Pamentioning

confidence: 99%

“…Many reports have indicated that the endothelin receptor antagonist bosentan is effective for improving clinical outcomes and exercise capacity in patients with Eisenmenger syndrome. 6,8,12,41) The BREATHE-5 trial (Bosentan Randomized Trial of Endothelin Antagonist Therapy-5) 8) is the only double-blind, placebo-controlled trial of pulmonary vasodilator therapy conducted in patients with Eisenmenger syndrome. The results of the BREATHE-5 trial showed that bosentan therapy significantly reduced Rp and improved the 6-minute walk distance compared with placebo.…”

Section: How Does Pulmonary Vasodilator Therapy Affect Outcomes In Pamentioning

confidence: 99%

“…44) Although there are no double-blind, placebo-controlled studies of the effects of phosphodiesterase-5 inhibitors in patients with CHD and PAH, a prospective open-label study found that sildenafil therapy was effective for improving pulmonary hemodynamics, functional class, and exercise tolerance with few significant side effects. 11,12) Unfortunately, evidence of the effectiveness of prostacyclin therapy for Eisenmenger syndrome is limited to small studies and case reports. 45,46) Fernandes, et al 47) reported that continuous intravenous epoprostenol therapy improved pulmonary hemodynamics, functional class, and exercise tolerance in patients with Eisenmenger syndrome.…”

Section: How Does Pulmonary Vasodilator Therapy Affect Outcomes In Pamentioning

confidence: 99%

See 2 more Smart Citations

Can Pulmonary Vasodilator Therapy Expand the Operative Indications for Congenital Heart Disease?

Inai

2015

Int. Heart J.

View full text Add to dashboard Cite

SummaryThe operability of congenital heart disease with left to right shunt depends on the severity of the pulmonary vascular disease induced by the increased pulmonary blood flow. Although some recommendations exist regarding operative indications according to pathological, hemodynamic, and epidemiological factors, the evidence underlying these recommendations is not conclusive. Recently, oral pulmonary vasodilator therapy has been reported to improve outcomes in patients with idiopathic pulmonary arterial hypertension, and this therapy also appears to be effective in patients with congenital heart disease and pulmonary arterial hypertension, including those with postoperative pulmonary hypertension and Eisenmenger syndrome. It is expected that the availability of novel pulmonary vasodilator therapy will expand the operative indications in patients with congenital heart disease with left to right shunt, but there is currently insufficient evidence to definitively determine this. A multicenter double-blind study should be conducted to further examine this issue. (Int Heart J 2015; 56: S12-S16)

show abstract

Impact of Sildenafil on Survival of Patients With Eisenmenger Syndrome

Sun

Yang

Zeng

et al. 2013

The Journal of Clinical Pharma

View full text Add to dashboard Cite

The favorable effects of short-term use of sildenafil on patients with Eisenmenger syndrome have been reported. We further studied the impact of long-term use of sildenafil on survival of these patients. In this study, the baseline data of patients newly diagnosed as Eisenmenger syndrome in our hospital between January 2005 and December 2009 were retrospectively collected. Patients were followed-up either by telephone contacts or during visits in our out-patient clinic. A total of 121 patients (68 patients in conventional group and 53 patients in sildenafil group) were finally included and 29 patients were re-evaluated after sildenafil therapy for 3-4 months. Compared with the baseline, a 6-minute walk distance, functional classes, plasma hemoglobin level, and hemodynamics were significantly improved after sildenafil treatment. During a median follow-up period of 35.8 months, 15 patients died (11 patients in conventional group). The 1- and 3-year survival rates in sildenafil group were 97.0% and 95.2%, significantly higher than 90.6% and 82.9% in conventional group P = .025). Multivariate analysis showed that sildenafil therapy, functional class and mean pulmonary arterial pressure were independently associated with survival. Therefore, long-term sildenafil therapy improved survival in patients with Eisenmenger syndrome.

show abstract

Bosentan–sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology

Cited by 110 publications

References 35 publications

The challenge of managing pulmonary arterial hypertension in adults with congenital heart disease

The challenge of managing pulmonary arterial hypertension in adults with congenital heart disease

Can Pulmonary Vasodilator Therapy Expand the Operative Indications for Congenital Heart Disease?

Impact of Sildenafil on Survival of Patients With Eisenmenger Syndrome

Contact Info

Product

Resources

About